Drug delivery to the central nervous system: General principles and relevance to therapy for infections of the central nervous system

Reviews of Infectious Diseases

Volumn 11, Issue , 1989, Pages S1669-S1690

  Scheld, W Michael ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI INFECTIVE AGENTS; ANTIINFECTIVE AGENT;

BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM DISEASE; HUMAN; INFECTION; REVIEW;

ANTI-INFECTIVE AGENTS; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM DISEASES; HUMAN; INFECTION;

EID: 0024756545     PISSN: 01620886     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/11.Supplement_7.S1669     Document Type: Article

References (214)

1. NorrbyR.A review of the penetration of antibiotics into CSF and its clinical significance.Scand J Infect Dis [Suppl]1978;14: 296-309
2. SandeMA, SherertzRJ, ZakO, DaceyRG, BodineJA, StrausbaughLJ.Factors influencing the penetration of antimicrobial agents into the cerebrospinal fluid of experimental animals.Scand J Infect Dis [Suppl]1978; 14: 160-3
3. NorrbyR.Pharmacokinetic aspects of the treatment of infections in the central nervous system.JAntimicrobChe- mother1979;5: 630-3
4. EverettED, StrausbaughLJ.Antimicrobial agents and the central nervous system.Neurosurgery1980: 6: 691-714
5. NorrbyR.Penetration of antimicrobial agents into cerebrospinal fluid: pharmacokinetics and clinical aspects. In: Wood JH, ed.Neurobiology of cerebrospinal fluid. New York: Plenum Publishing Corp1980;449-63
6. SandeMA.Factors influencing the penetration and activity of antibiotics in experimental meningitis.J Infect1981;3(Suppl 1): 33-8
7. RichardsML, PrinceRA, KenaleyKA, JohnsonJA, Le FrockJL.Antimicrobial penetration into cerebrospinal fluid.DrugIntellClin Pharm1981;15: 341-68
8. ScheidWM.Rationale for optimal dosing of beta-lactam antibiotics in therapy for bacterial meningitis.Eur J ClinMicrobiol1984;3: 579-91
9. ScheidWM.Theoretical and practical considerations of antibiotic therapy for bacterial meningitis.Pediatr Infect Dis1985: 4: 74-83
10. PlordeJJ, GarciaM, PetersdorfRG.Studies on the pathogenesis of meningitis.IV. Penicillin levels in the cerebrospinal fluid in experimental meningitis. J Lab Clin Med1964;64: 960-9
11. BeamTR, AllenJC.Blood, brain, and cerebrospinal fluid concentrations of several antibiotics in rabbits with intact and inflamed meninges.Antimicrob Agents Chemo- ther1977;12: 710-6
12. MüllerC, NetlandA, DawsonAF, AndrewE.The penetration of cefuroxime into the cerebrospinal fluid through inflamed and non-inflamed meninges.JAntimicrobChe- mother1980;6: 279-83
13. KrontzDP, StrausbaughLJ.Effect of meningitis and probenecid on the penetration of vancomycin into cerebrospinal fluid in rabbits.Antimicrob Agents Chemo- ther1980;18: 882-6
14. HieberJP, NelsonJD.A pharmacologic evaluation of penicillin in children with purulent meningitis.NEngl J Med1977;297: 410-3
15. CraftJC, FeldmanWE, NelsonJD.Clinicopharmacological evaluation of amoxicillin and probenecid against bacterial meningitis.Antimicrob Agents Chemother1979; 16: 346-52
16. FeldmanWE, MoffitS, ManningNS.Penetration of cefoxitin into cerebrospinal fluid of infants and children with bacterial meningitis.Antimicrob Agents Chemother1982; 21: 468-71
17. NolanCM, McAllisterCK, WaltersE, BeatyHN.Experimental pneumococcal meningitis.IV. The effect of methylprednisolone on meningeal inflammation. J Lab Clin Med1978;91: 979-88
18. ScheidWM, BrodeurJP.Effect of methylprednisolone on entry of ampicillin and gentamicin into cerebrospinal fluid in experimental pneumococcal and Escherichia coli meningitis.Antimicrob Agents Chemother1983;23: 108-12
19. LernerPI.Selection of antimicrobial agents in bacterial infections of the central nervous system.AdvNeurol1964; 6: 169-95
20. BradburyM.The concept of a blood-brain barrier.Chichester, UK: John Wiley and Sons, 1979
21. RapoportSI.The blood-brain barrier in physiology and medicine.New York: Raven Press, 1976: 139-40, 178-82
22. BarzaM, BrownRB, ShanksC, GambleC, WeinsteinL.Relation between lipophilicity and pharmacological behavior of minocycline, doxycycline, tetracycline and Oxytetracycline in dogs. Antimicrob Agents Chemother1975;8: 713-20
23. BarlowCF.Clinical aspects of the blood-brain barrier.Annu Rev Med1964;15: 187-203
24. TaberLH, YowMD, NiebergFG.The penetration of broad- spectrum antibiotics into the cerebrospinal fluid.Ann NY AcadSei1967;145: 473-81
25. RailDP, Stabenau, ZubrodCG.Distribution of drugs between blood and cerebrospinal fluid: general methodology and effect of pH gradients. J PharmacolExpTher1959;125: 185-93
26. FishmanRA.Blood-brain and CSF barriers to penicillin and related organic acids.Arch Neurol1966;15: 113-24
27. LorenzoAV, SpectorR.The distribution of drugs in the central nervous system.AdvExp Med Biol1976;69: 447-62
28. KuninCM.Effect of serum binding on the distribution of penicillins in the rabbit. J Lab Clin Med1965;65: 406-15
29. RuedyJ.The concentrations of penicillins in the cerebrospinal fluid and brain of rabbits with experimental meningitis.Can J PhysiolPharmacol1965;43: 763-72
30. StrausbaughLJ, MurrayTW, SandeMA.Comparative penetration of six antibiotics into the cerebrospinal fluid of rabbits with experimental staphylococcal meningitis.JAntimicrobChemother1980;6: 363-7.
31. DixonRL, OwensES, RailDP.Evidence of active transport of benzyl-‘4C-penicillin from cerebrospinal fluid to blood.J Pharm Sei1969;58: 1106-9
32. PollayM.Transport mechanisms in the choroid plexus.Fed Proc1974;33: 2064-9
33. SpectorR, LorenzoAV.The effects of salicylate and probenecid on the cerebrospinal fluid transport of penicillin, aminosalicylic acid, and iodideJ PharmacolExpTher1974;188: 55-65
34. SpectorR, LorenzoAV.Inhibition of penicillin transport from the cerebrospinal fluid after intracisternal inoculation of bacteria. J Clin Invest1974;54: 316-25
35. DaceyRG, SandeMA.Effect of probenecid on cerebrospinal fluid concentrations of penicillin and cephalosporin derivatives.Antimicrob Agents Chemother1974;6: 437-41
36. SpectorR.Ceftriaxone pharmacokinetics in the centra) nervous system.J PharmacolExpTher1986;236: 380-3
37. OldendorfWH.Brain uptake of metabolites and drugs following carotid arterial injections.Transactions of the American Neurological Association1971;96: 46-50
38. PardridgeWM, ConnorJD, CrawfordIL.Permeability changes in the blood-brain barrier: causes and consequences. CRC Crit Rev Toxicol1975;3: 159-99
39. SpectorR, SivesindC, KinzenbawD.Pantothenic acid transport through the blood-brain barrier. J Neurochem1986;47: 966-71
40. SpectorR.Ceftriaxone transport through the blood-brain barrier. J Infect Dis1987;156: 209-11
41. IkkasatoY, RapoportSI, SmithQR.An in situ brain perfusion technique to study cerebrovascular transport in the rat.Am J Physiol1984;247: H484-93
42. MeulemansA, VicartP, HenzelD, MohlerJ, VulpillatM.Cefsulodin penetration into rat brain: extracellular versus total concentration. Chemother1986;32: 393-8
43. BeamTR.AllenJC.Assessment of antibiotic efficacy in acute bacterial meningitis.ClinPharmacolTher1979; 25: 199-203
44. OftedahlPR, WinnG, RodeheaverG, HoriwitzM, FenstermacherJD.Changes in regional cerebral blood flow and blood brain barrier permeability in experimental brain abscess. J Cereb Blood Flow Metab1981;1(Suppl): S38
45. WellmanWE, DodgeHW, HeilmanFR, PetersenMC.Concentration of antibiotics in the brain.J Lab Clin Med1954;43: 275-9
46. KramerPW, GriffithRS, CampbellRL.Antibiotic penetration of the brain.A comparative study.J Neurosurg1969;31: 295-302
47. BlackP, Graybill, CharacheP.Penetration of brain abscess by systemically administered antibiotics.J Neurosurg1973;38: 705-9
48. deLouvoisJ, GortvaiP, HurleyR.Antibiotic treatment ofabscesses of the central nervous system. Br Med J1977; 2: 985-7
49. deLouvoisJ, HurleyR.Inactivation of penicillin by purulent exudates. Br Med J1977;1: 998-1000
50. PicardiJL, LewisHP, TanJS, PhairJP.Clindamycin concentrations in the central nervous system of primates before and after head trauma.J Neurosurg1975;43: 717-20
51. InghamHR, SelkonJB, RoxbyCM.Bacteriologicalstudyofotogenic cerebral abscesses: chemotherapeutic role of metronidazole. Br Med J1977;2: 991-3
52. AldersonD, StrongAJ, InghamHR, SelkonJB.Fifteenyear review of the mortality of brain abscess.Neurosurgery1981;8: 1-6
53. SmegoRA, MoellerMB, GallisHA.Trimethoprimsulfamethoxazole therapy for nocardiainfections.Arch Intern Med1983;143: 711-8
54. MaderazoEG, QuintilianiR.Treatment of nocardial infection with trimethoprim and sulfamethoxazole.Am J Med1974;57: 671-5
55. LevitzRE, QuintilianiR.Trimethoprim-sulfamethoxazolefor bacterial meningitis.Ann Intern Med1984;100: 881-90
56. 'GreeneBM, ThomasFE, AlfordRH.Trimethoprimsulfamethoxazole and brain abscess. Ann Intern Med1975;82: 812-3
57. LevyRM, GutinPH, BaskinDS, PonsVG.Vancomycinpenetration of a brain abscess: Case report and review of the literature. Neurosurgery1986;18: 632-6
58. PreheimLC, McCrackenGH, JubelirerDP, SandersCC, BarrettFF.Moxalactam penetration into brain abscess [abstract no. 738], In: Program and abstracts of the 21st Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC:American Society for Microbiology, 1981
59. MarcusMG, AtluruVL, EpsteinNE, LeggiadroRJ.Conservative management of Citrobacterdiversus meningitis with brain abscess.NY State J Med1984;84: 252-4
60. ScheldWM, BrodeurJP, ForesmanPA, GratzJC, RodeheaverGT, Comparative evaluation of aztreonam in therapy for experimental bacterial meningitis and cerebritis. Rev Infect Dis1985;7(Suppl 4): S635-47
61. NeuHC.Uses of antimicrobial agents in brain abscesses.In: Nelson JD, Grassi C, eds.Current chemotherapy and infectious disease. Vol1.Washington, DC: American Society for Microbiology, 1980: 41-2
62. EhrlichP.DasSauerstoff-Bedürfnis des Organismus: einefarbenanalytischeStudie. Berlin: Hirschward, 1885
63. GoldsteinGW, BetzAL.The blood-brain barrier.Sei Am1986;255(3): 74-83
64. LaneNJ.A comparison of the construction of intercellular junctions in the CNS of vertebrates and invertebrates.Trends in Neuroscience1984;7: 95-9
65. PardridgeWM, OldendorfWH, CancillaP, FrankHJL.Blood-brain barrier: interface between internal medicine and the brain. Ann Intern Med1986;105: 82-95
66. BradburyM.Why a blood-brain barrier?Trends in Neuroscience1979;2: 36-8
67. Wolff.The astrocyte as link between capillary and nervecell.Triangle1970;9: 153-64
68. ReeseT, KarnovskyM.Fine structural localization of ablood-brain barrier to exogenous peroxidase. J Cell Biol1967;34: 207-17
69. BrightmanMW, ReeseTS.Junctions between intimately apposed cell membranes in the vertebrate brain.J Cell Biol1969;40: 648-77
70. BrighmanMW.Morphology of blood-brain interfaces.ExpEye Res1977;25(Suppl)!-25
71. OldendorfWH, CornfordME, BrownWJ.The large apparent work capability of the blood-brain barrier: a study of the mitochondrial content of capillary endothelial cells in brain and other tissues of the rat. Ann Neurol1977; 1: 409-17
72. BradburyMWB.The structure and function of the blood-brain barrier.Fed Proc1984;43: 186-90
73. BärT, GüldnerF-H, Wolff. “Seamless” endothelial cellsof blood capillaries. Cell Tissue Res1984;235: 99-106
74. CoomberBL, StewartPA.Morphometrie analysis of CNSmicrovascularendothelium.Microvasc Res1985;30: 99-115
75. StewartPA, WileyMJ.Structural and histochemical features of the avian blood-brain barrier.J Comp Neurol1981;202: 157-67
76. StewartPA, WileyMJ.Developing nervous tissue inducesformation of blood-brain barrier characteristics in invading endothelial cells: a study using quail-chick transplantation chimeras. DevBiol1981;84: 183-92
77. JefferiesWA, BrandonMR, HuntSV, WilliamsAF, GatterKC, MasonDY.Transferrin receptor on endothelium of brain capillaries.Nature1984;312: 162-3
78. RisauW, HallmannR, AlbrechtU.Differentiation-dependent expression of proteins in brain endothelium during development of the blood-brain barrier. DevBiol1986;117: 537-45
79. DermietzelR.Junctions in the central nervous system ofthecat.IV.Interendothelial junctions of cerebral blood vessels from selected areas of the brain. Cell Tissue Res1975;164: 46-62
80. ShiversRR, BetzAL, GoldsteinGW.Isolated rat brain capillaries possess intact, structurally complex, inteFendothelial tight junctions; freeze-fracture verification of tight junction integrity. Brain Res1984;324: 313-22
81. CroneC, OlesenSP.Electrical resistance of brain microvascularendothelium.Brain Res1982;241: 49-55
82. OldendorfWH.The blood-brain barrier.In: Lajtha A, ed.Handbook of neurochemistry. Vol7.New York: Plenum, 1984: 485-99
83. BetzAL, GilboeDD, DrewesLR.The characteristics of glucose transport across the blood-brain barrier and its relation to cerebral glucose metabolism. In: Levi G, Bat- tistin L, Lajtha A, eds.Transport phenomena in the nervous system. New York: Plenum, 1978: 133-49
84. Lund-AndersenH.Transport of glucose from blood to brain. Physiol Rev1979;59: 305-52
85. PardridgeWM.Brain metabolism: a perspective from theblood-brain barrier. Physiol Rev1983;63: 1481-535
86. BetzAL, CsejteyJ, GoldsteinGW.Hexose transport andphosphorylation by capillaries isolated from rat brain. Am J Physiol1979;236: C96-102
87. BetzAL, GoldsteinGW.Development changes in metabolism and transport properties of capillaries isolated from rat brain. J Physiol1981;312: 365-76
88. GoldsteinGW.Relationof potassium transport to oxidative metabolism in isolated brain capillaries.J Physiol1979;286: 185-95
89. DickAPK, HarikSI, KlipA, WalkerDM.Identificationand characterization of the glucose transporter of the blood-brain barrier by cytochalasin B binding and immunological reactivity. ProcNatlAcadSei USA1984; 81: 7233-7
90. SershenH, LajthaA.Inhibition pattern by analogs indicates the presence of ten or more transport systems for amino adds in brain cells. J Neurochem1979;32: 719-26
91. BrustP.Changes in regional blood-brain transfer of L-leucineelicited by arginine-vasopressin. J Neurochem1986;46: 534-41
92. BetzAL, GoldsteinGW.Specialized properties and solutetransport in brain capillaries. Ann Rev Physiol1986;48: 241-50
93. BetzAL, FirthJA, GoldsteinGW.Polarity of the blood brain barrier: distribution of enzymes between the luminal and antiluminal membranes of the brain capillary endothelial cell. Brain Res1980;192: 17-28
94. SpatzM.Attenuated blood-brain barrier.In: Lajtha A, ed.Handbook of neurochemistry.New York: Plenum, 1984;7: 501-43
95. DernovsekKD, BarRS.Processing of cell-bound insulinby capillary and macrovascular endothelial cells in culture.Am J Physiol1985;248: E244-51
96. FrankHJL, PardridgeWM.A direct in vitro demonstration of insulin binding to isolated brain microvessels. Diabetes1981;30: 757-61
97. PardridgeWM, EisenbergJ, YangJ.Human blood-brainbarrier insulin receptor. J Neurochem1985;44: 1771-8
98. FrankHJL, Jankovic-VokesT, PardridgeWM, MorrisWL.Enhanced insulin binding to blood-brain barrier in vivo and to brain microvessels in vitro in newborn rabbits.Diabetes1985: 34: 728-33
99. FrankHJL, PardridgeWM, MorrisWL, RosenfeldRG, ChoiTB.Binding and internalization of insulin and insulin-like growth factors by isolated brain microvessels. Diabetes1986;35: 654-61
100. PardridgeWM.Kinetics of competitive inhibition of neutral amino acid transport across the blood-brain interface.JNeurochem1977;28: 103-8
101. Hardebo JE, Owman C.Barrier mechanisms for neurotransmitter monoamines and their precursors at the blood- brain barrier. Ann Neurol1980;8: 1-11
102. JooF.New aspects to the function of the cerebralndothelium.Nature1986;321: 197-8
103. DeBaultLE, CancillaPA.Gamma-glutamyltranspeptidasein isolated brain endothelial cells: induction by glial cells in vitro. Science1980;207: 653-5
104. BeckDW, VintersHV, HartMN, CancillaPA.Glialcellsinfluence the polarity of the blood-brain barrier. J Neu- ropatholExpNeurol1984;43: 219-24
105. BeckDW, RobertsRL, OlsonJJ.Glial cells influencemembrane-associated enzyme activity at the blood-brain barrier. Brain Res1986;381: 131-7
106. Neu weltEA, ed.Implications of the blood-brain barrier andits manipulation. Vol2.Clinical aspects.New York: Plenum Press, 1988
107. MoxonE, OstrowP.Haemophilusinfluenzaemeningitisin infant rats: role of bacteremia in pathogenesis of age dependent inflammatory responses in cerebrospinal fluid. J Infect Dis1977;135: 303-7
108. QuagliarelloVJ, LongWJ, ScheidWM.Morphologic alterations of the blood-brain barrier with experimental meningitis in the rat: temporal sequence and role of encapsulation. J Clin Invest1986;77: 1084-95
109. QuagliarelloVJ, ScheidWM.Recent advances in the pathogenesis and pathophysiology of bacterial meningitis. Am J Med Sei1986;292: 306-9
110. ScheidWM, QuagliarelloVJ, LesseAJ.Selected aspects ofthe pathogenesis and pathophysiology of bacterial meningitis.In: O’Grady F, Williams JD, eds.Bacterial meningitis. London: Academic Press, 1987: 1-28
111. CooperAJ, BeatyHN, OppenheimerSI, GoodnerCJ, PetersdorfRG. Studies on the pathogenesis of meningitis.VII.Glucose transport and spinal fluid production in the experimental pneumococcal meningitis. J Lab Clin Med1968;71: 473-83
112. ProckopLD, Fishman RA.Experimental neumococcalmeningitis.Permeability changes influencing the concentration of sugars and macromolecules in cerebrospinal fluid.Arch Neurol1968;19: 449-63
113. NelsonE, BlinzingerK, HagerH.An electron microscopicstudy of bacterial meningitis.I.Experimental alterations in the leptomeninges and subarachnoid space.Arch Neurol1962;6: 390-403
114. GoldsteinGW, WolinskyJS, CsejteyJ, DiamondI.Isolation of metabolically active capillaries from rat brain.J Neurochem1975;25: 715-7
115. GoldsteinGW, BetzAL.Recent advances in understandingbrain capillary function. Ann Neurol1983;14: 389-95
116. McCallAL, MillingtonWR, WurtmanRJ.Metabolicfueland amino acid transport into the brain in experimental diabetes mellitus. ProcNatl Ac Sei USA1982;79: 5406-10
117. NuttJG, WoodwardWR, HammerstadJP, CarterJH, AndersonJL.The “on-off” phenomenon in Parkinson’s disease: relation to levodopa absorption and transport. N Engl J Med1984;310: 483-8
118. CradockJC, KleinmanLM, DavignonJP.Intrathecal injections: a review of pharmaceutical factors. Bull Parent Drug Assoc1977;31: 237-47
119. OnofrioBM, YakshTL, ArnoldPG.Continuous low-doseintrathecal morphine administration in the treatment of chronic pain of malignant origin.Mayo ClinProc1981;56: 516-20
120. FenstermacherJD, BlasbergRG, PatlakCS.Methodsforquantifying the transport of drugs across brain barrier systems. PharmacolTher1981;14: 217-48
121. GreigNH.Chemotherapy of brain métastasés: current status. Cancer Treat Rev1984;11: 157-86
122. GreigN.Drug delivery to the brain by blood brain barriercircumvention and drug modification.In: Neuwelt EA, ed.Implications of the blood-brain barrier and its manipulation.Vol2.New York: Plenus Press, 1988
123. BlasbergR, PatlakC, ShapiroW.Distribution of methotrexate in the cerebrospinal fluid and brain after intraven- tricularadministration.Cancer Treat Rep1977;61: 633-41
124. RubinRC, OmmayaAK, HendersonES, BeringEA, RailDP.Cerebrospinal fluid perfusion for central nervous system neoplasms.Neurology1966;16: 680-92
125. MadajewizcS, WestCR, ParkHC, GhoorahJ, AvellanosaAM, TakitaH, KarakousisC, VincentR, CaracandasJ, JenningsE.Phase II study: intraarterial BCNU therapy for metastatic brain tumors. Cancer1981;47: 653-7
126. HanschC.A quantitative approach to biochemical structure-activity relationships.Accounts of Chemical Research1969;2: 232-9
127. HanschC.Strategy in drug design.CancerChemother Rep1972;56: 433-41
128. GreigNH, MommaS, SweeneyDJ, SmithQR, RapoportSI.Facilitated transport of melphalan at the rat blood- brain barrier by the large neutral amino acid carrier system.Cancer Res1987;47: 1571-6
129. MommaS, GreigNH, SmithQR, RapoportSI.Facilitatedtransport of melphalan at the blood-brain barrier by the large neutral amino acid carrier system [abstract no. 1408].Proceedings of the American Association for Cancer Research1985;26: 357
130. BodorN, FaragHH, BrewsterME.Site-specific, sustained release of drugs to the brain.Science1981;214: 1370-2
131. FeunLG, LeeYY, WallaceS, CharnsangavejC, SavarajN, CarrascoCH, GianturcoC, YungWKA.New drugs and new delivery techniques.ProgExp T\imor Res1985;29: 131-9
132. BodorN, BrewsterME.Problems of delivery of drugs tothebrain.PharmacolTher1983;19: 337-86
133. RandKH, BodorN, El KoussiAA, RaadI, MiyakeA, HouckH, GildersleeveN.Potential treatment of herpes simplex virus encephalitis by brain-specific delivery of trifluorothymidine using a dihydropyridine in equilibrium pyridinium salt type redox delivery system. J Med Virol1986;20: 1-8
134. ParkN, Pavan-LangstonD, McLeanSL, AlbertDM.Therapy of experimental herpes simplex encephalitis with acyclovir in mice.Antimicrob Agents Chemothe1979; 15: 775-9
135. Bakker-WoudenbergIAJM, RoerdinkFH.Antimicrobialchemotherapy directed by liposomes. J AntimicrobChemother1986;17: 547-9
136. Lopez-BeresteinG.Liposomes as carriers of antimicrobialagents. Antimicrob Agents Chemother1987;31: 675-8
137. Lopez-BeresteinG, KasiL, RosenblumMG, HaynieT, JahnsM, GlennH, MehtaR, MavligitGM, HershEM.Clinical pharmacology ofTc-labeled liposomes in patients with cancer.Cancer Res1984;44: 375-8
138. Lopez-BeresteinG, FainsteinV, HopferR, MehtaK, SullivanMP, KeatingM, RosenblumMG, MehtaR, LunaM, HershEM, ReubenJ, JulianoRL, BodeyGP.Liposomal-amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary report. J Infect Dis1985;151: 704-10
139. Lopez-BeresteinG, BodeyGP, FrankelLS, MehtaK.Tieatment of hepatospleniccandiasis with liposomalampho- tericin B. J ClinOncol1987;5: 310-7
140. MeunierF.New methods for delivery of antifungal agents.Rev Infect Dis 1989;11(Suppl7): S1605-12
141. GabizonA, DaganA, GorenD, BarenholzY, FuksZ.Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice.Cancer Res1982;42: 4734-9
142. McKernanRO, FirthG, OliverS, UttleyD, O’LaoireS.Apotential application for the intracerebral injection of drugs entrapped within liposomes in the treatment of human cerebral gliomas. J NeurolNeurosurg Psychiatry1985;48: 1213-9
143. BromanT, OlssonO.Experimental study of contrast media for cerebral angiography with reference to possible injurious effect on the cerebral blood vessels. ActaRadiologica1949;31: 321-34
144. RapoportSI.Effect of concentrated solutions on blood-brainbarrier.Am J Physiol1970;219: 270-4
145. RapoportSI, HoriM, KlatzoI.Testing of a hypothesis forosmotic opening of the blood-brain barrier. Am J Physiol1972;223: 323-31
146. BrightmanMW, HoriM, RapoportSI, ReeseTS, WestergaardE.Osmotic opening of tight junctions in cerebral endothelium. J Comp Neurol1973;152: 317-25
147. RapoportSI, RobinsonPJ.Tight-junctionalmodificationas the basis of osmotic opening of the blood-brain barrier.Ann NY AcadSci1986;481: 250-67
148. MayhanWG, HeistadDD.Permeability of the blood-brainbarrier to various sized molecules. Am J Physiol1985; 248: H712-8
149. Dorovini-ZisK, BowmanPD, BetzAL, GoldsteinGW.Hyperosmotic arabinose solutions open the tight junctions between brain capillary endothelial cells in tissue culture. Brain Res1984;302: 383-6
150. RapoportSI, MatthewsK, ThompsonHK, PettigrewKD.Osmotic opening of the blood-brain barrier in the rhesus monkey without measurable brain edema.Brain Res1977;136: 23-9
151. HasequaH, AllenJE, MehtaBM, ShapiroWR, PosnerJB.Enhancement of CNS penetration of methotrexate by hyperosmolar intracarotidmannitol or carcinomatous meningitis.Neurology1979;29: 1280-6
152. NeuweltEA, FrenkelEP, RapoportSI, BarnettP.Effectof osmotic blood-brain barrier disruption on methotrexate pharmacokinetics in the dog. Neurosurg1980;7: 36-43
153. OhnoK, FredericksWR, RapoportSI.Osmoticopeningof the blood-brain barrier to methotrexate in the rat.SurgNeurol1979;12: 323-8
154. NeuweltEA, BalabanE, DiehlJ, HillS, FrenkelE.Successful treatment of primary central nervous system lymphomas with chemotherapy after osmotic blood-brain barrier opening. Neurosurgery1983;12: 662-71
155. FenstermacherJ, GazendamJ.Intra-arterial infusions ofdrugs and hyperosmotic solutions as ways of enhancing CNS chemotherapy. Cancer TVeat Rep1981;65(Suppl 2): 27-37
156. NeuweltEA, BakerDE, PagelMA, BlankNK.The cerebrovascular permeability and delivery of gentamicin to normal brain and experimental brain abscess in rats. J Neurosurg1984;61: 430-9
157. ZiylanYZ, RobinsonPJ, RapoportSI.Blood-brain barrierpermeability to sucrose and dextran after osmotic opening.Am J Physiol1984;247: R634-8
158. NeuweltEA, BarnettPA, McCormickCL, FrenkelEP, MinnaJD.Osmotic blood-brain barrier modification: monoclonal antibody, albumin, and methotrexate delivery to cerebrospinal fluid and brain. Neurosurgery1985;17: 419-23
159. NeuweltEA, MinnaJ, FrenkelE, BarnettPA, McCormickCL.Osmotic blood-brain barrier opening to IgM monoclonal antibody in the rat. Am J Physiol1986;250: R875-83
160. NeuweltEA, HowiesonJ, FrenkelEP, SpechtHD, WeigelR, BuchanCG, HillSA.Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood-brain barrier modification in glioblastoma.Neurosurgery1986;19: 573-82
161. GreigN, HellmannK.Enhanced cerebrovascular permeability by metrazol: significance for brain metastases. ClinExpMetast1983;1: 83-95
162. GreigN, NewellD, Hellmann K.Metrazol enhances brainpenetration and therapeutic efficacy of some anticancer agents: Implications for brain metastases. ClinExpMetast1984;2: 55-9
163. BroadwellRD, SalcmanM.Expanding the definition of theblood-brain barrier to protein. ProcNatlAcadSci USA1981;78: 7820-4
164. BroadwellRD, SalcmanM, KaplanRS.Morphologic effect of dimethyl sulfoxide on the blood-brain barrier.Science1982;217: 164-6
165. GreigNH, SweeneyDJ, RapoportSI.Inability of dimethylsulfoxide to increase brain tumors.CancerTteat Rep1985;69: 305-12
166. NeuweltEA, BarnettP, BarrangerJ, McCormickC, PagelM, FrenkelE.Inability of dimethylsulfoxide and 5-fluo- rouracil to open the blood-brain barrier. Neurosurgery1983: 12: 29-34
167. IwenPC, MillerNG.Enhancement of ketoconazole penetration across the blood-brain barrier of mice by dimethylsulfoxide.Antimicrob Agents Chemother1986;30: 617-8
168. SpigelmanMK, ZappullaRA, JohnsonJ, GoldsmithSJ, MalisLI, HollandJF.Etoposide-induced blood-brain barrier disruption.Effect of drug compared with that of solvents. J Neurosurg1984;61: 674-8
169. SpigelmanMK, ZappullaRA, StrauchenJA, FeuerEJ, JohnonJ, GoldsmithSJ, MalisLI, HollandJF.Etoposide- induced blood-brain barrier disruption in rats: duration of opening and histological sequelae. Cancer Res1986; 46: 1453-7
170. HollisPH, ZappullaRA, SpigelmanMK, FeuerEJ, JohnsonJ, HollandJF, MalisLI.Physiological and electro- physiological consequences of etoposide-induced blood- brain barrier disruption. Neurosurgery1986;18: 581-6
171. SpigelmanM, ZappullaRA, MalisLI, HollandJF, GoldsmithSJ, GoldbergJD.Intracarotiddehydrocholate infusion: a new method for prolonged reversible blood-brain barrier disruption. Neurosurgery1983;12: 606-12
172. KimYS, LeeMH, WisniewskiHM.Aluminum induced reversible change in permeability of the blood-brain barrier to, 4C-sucrose. Brain Res1986;377: 286-91
173. NagyZ, PetersH, HüttnerI.Endothelial surface charge: blood-brain barrier opening to horseradish peroxidase induced by the polycation protamine sulfate. ActaNeu- ropathol [Suppl] (Berlin)1981;7: 7-9
174. ScheidWM, SandeMA.Bactericidal vs. bacteriostatic antibiotic therapy of experimental pneumococcal meningitis in rabbits.JClin Invest1983;71: 411-9
175. SiegelJD, McCrackenGH.Sepsisneonatorum.N EnglJMed1981;304: 642-7
176. BerkSL, McCabeWR.Meningitis caused by gram-negativebacilli. Ann Intern Med1980;93: 253-60
177. GowerDJ, BarrowsAA III, KellyDL, PegramS. Gramnegative bacillary meningitis in the adult: review of 39 cases. South Med J1986;79: 1499-502
178. CroweHM, LevitzRE.InvasiveHaemophilusinfluenzadisease in adults.Arch Intern Med1987;147: 241-4
179. McCrackenGH, ThrelkeldN, MizeS, BakerCJ, KaplanSLK, FaingezichtI, FeldmanWE, SchaadU, Neonatal Meningitis Cooperative Study Group. Moxalactam therapy for neonatal meningitis due to gram-negative enteric bacilli.A prospective controlled evaluation.JAMA1984; 252: 1427-32
180. CherubinCE, MarrJS, SierraMF, Becker S.Listeria andgram-negative bacillary meningitis in New York City, 1972-1979. Frequent causes of meningitis in adults.Am J Med1981;71: 199-209
181. SchaadUB, McCrackenGH, LoockCA, ThomasML.Pharmacokinetics and bacteriological efficacy of moxo- lactam (LY 127935), netilmicin and ampicillin in experimental gram-negative enteric bacillary meningitis. Antimicrob Agents Chemother1980;17: 406-11
182. McCrackenGH, SchaadUB.The pharmacologic basisformoxalactam therapy for gram-negative enteric bacillary meningitis of infancy.Rev Infect Dis1982;4(Suppl): S603-5
183. SchaadUB, McCrackenGH, LoockCA, ThomasML.Pharmacokinetics and bacterilogic efficacy of moxalactam, cefotaxime, cefoperazone and rocephin in experimental bacterial meningitis. J Infect Dis1981: 143: 156-63
184. SakataY, BoccazziA, McCrackenGHPharmacokinetics and bacteriological effect of ceftazidime in experimental Streptococcus pneumoniae, Haemophilusinfluenzae and Escherichia coli meningitis. Antimicrob Agents Chemother1983;23: 213-7
185. LatifR, DajaniAS.Ceftriaxone diffusion into cerebrospinal fluid of children with meningitis.Antimicrob Agents Chemother1983;23: 46-8
186. LandesmanSH, CherubinCE, CorradoML.Gram-negativebacillarymeningitis.New therapy and changing concepts.Arch Intern Med1982;142: 939-40
187. CherubinCE, CorradoML, NairSR, GombertME, LandesmanSH, HumbertG.Tireatment of gram-negative bacillary meningitis: role of the new cephalosporin antibiotics. Rev Infect Dis1982;4(SuppI): S453-67
188. RahalJJ, SimberkoffMS, LandesmanSH, Metropolitan Meningitis Study Group. Prospective evaluation of moxalactam therapy for gram-negative bacillary meningitis.J Infect Dis1984;149: 562-8
189. CherubinCE, EngRHK.Experience with the use of cefotaxime in the treatment of bacterial meningitis.Am J Med1986;80: 398-404
190. FongIW, TopkinsKB.Review of Pseudomonas aeruginosameningitis with special emphasis on treatment with ceftazidime. Rev Infect Dis1985: 7: 604-12
191. SchaadUB.Treatment of bacterial meningitis.Eur J ClinMicrobiol1986;5: 492-7
192. BryanJP, RochaH, Da SilvaHR, TaveresA, SandeMA, ScheldWM.Comparison of ceftriaxone and ampicillin plus chloramphenicol for the therapy of acute bacterial meningitis. Antimicrob Agents Chemother1985;28;361-8
193. KleinJO, FeiginRD, McCrackenGH. Report of the TaskForce on Diagnosis and Management of Meningitis. Pediatrics1986;78: 959-82
194. Whitby M, Finch R. Bacterialmeningitis. Rationale selection and use of antibacterial drugs.Drugs1986;31: 266-78
195. McCrackenGH, NelsonJD, KaplanSL, OverturfGD, RodriguezWJ, SteeleRW.Consensus report: antimicrobial therapy for bacterial meningitis in infants and children. Pediatr Infect Dis J1987;6: 501-5
196. KaplanSL, FishmanMA.Supportive therapy for bacterialmeningitis.Pediatr Infect Dis J1987;6: 670-7
197. HollanderH, LevyJA.Neurologic abnormalities and recovery of human immunodeficiency virus from cerebrospinal fluid.Ann Intern Med1987;106: 692-5
198. LevyRM, BredesenDE, RosenblumML.Neurologicalmanifestations of the acquired immunodeficiency syndrome (AIDS): experience at UCSF and review of the literature. J Neurosurg1985;62: 475-95
199. SniderWD, SimpsonDM, NielsonS, GoldJWM, MetrokaCE, PosnerJB.Neurological complications of acquired immune deficiency syndrome: analysis of 50 patients. Ann Neurol1983;14: 403-18
200. NaviaBA, JordonBD, PriceRW.The AIDS dementia complex: I. Clinical features. Ann Neurol1986;19: 517-24
201. NaviaBA, ChoES, PetitoCK, PriceRW.The AIDS dementia complex: II. Neuropathology.Ann Neurol1986; 19: 525-35
202. ShawGM, HarperME, HahnBH, EpsteinLG, GajdusekDC, PricePW, NaviaBA, PetitoCK, O’HaraC J, Groop- manJE, ChoES, OleskeJM, Wong-StaalF, GalloRC.HTLV-III infection in brains of children and adults with AIDS encephalopathy.Science1985;227: 177-82
203. LevyJA, ShimabukuroJ, HollanderH, MillsJ, KaminskyL.Isolation of AIDS-associated retroviruses from cerebrospinal fluid and brain of patients with neurological symptoms. Lancet1985;2: 586-8
204. KoenigS, GendelmanHE, OrensteinJM, Dal CantoMC, PezeshkpourGH, YungbluthM, JanottaF, AksamitA, MartinMA, FauciAS.Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy.Science1986;233: 1089-93
205. WileyCA, SchrierRD, NelsonJA, LampertPW, OldstoneMBA.Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients.ProcNatlAcadSei USA1986;83: 7089-93
206. GyorkeyF, MelnickJL, GyorkeyP.Human immunodeficiency virus in brain biopsies of patients with AIDS and progressive encephalopathy. J Infect Dis1987;155: 870-6
207. KoyanagiY, MilesS, MitsuyasuRT, MerrillJE, VintersHV, ChenISY.Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms.Science1987;236: 819-22
208. BarnesDM.Brain damage by AIDS under active study.Science1987;235: 1574-7
209. De VitaVT, BroderS, FauciAS, KovacsJA, ChabnerBA.Developmental therapeutics and the acquired immunodeficiency syndrome.Ann Intern Med1987;106: 568-81
210. VogtM, HirschMS.Prospects for the prevention and therapy of infections with the human immunodeficiency virus. Rev Infect Dis1986;8: 991-1000
211. YarchoanR, Broder S. Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders. A progress report.NEngl J Med1987; 316: 557-64
212. HirschMS, KaplanJC.Treatment of human immunodeficiency virus infections.Antimicrob Agents Chemother1987;31: 839-43
213. YarchoanR, WeinholdKJ, LyerlyHK, GelmannE, BlumRM, ShearerGM, MitsuyaH, CollinsJM, MyersCE, KleckerRW, MarkhamPD, DurackDT, LehrmanSN, BarryDW, FischlMA, GalloRC, BolognesiDP, BroderS.Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet1986;1: 575-80
214. YarchoanR, BrouwersP, SpitzerAR, GrafmanJ, SafaiB, PernoCF, LarsonSM, BergG, FischlMA, WichmanA, ThomasRV, BrunettiA, SchmidtPJ, MyersCE, BroderS.Response of human-immunodeficiency-virus-associated neurological disease to 3'azido-3'-deoxythymidine. Lancet1987;1: 132-5